BMY Aug 2024 60.000 call

OPR - OPR Delayed Price. Currency in USD

Add to watchlist

0.0600

+0.0100

(+20.00%)

As of 03:22PM EDT. Market open.

Loading interactive chart...

Simply Wall St.
Bristol-Myers Squibb First Quarter 2024 Earnings: Revenues Beat Expectations, EPS Lags
Bristol-Myers Squibb ( NYSE:BMY ) First Quarter 2024 Results Key Financial Results Revenue: US$11.9b (up 4.7% from 1Q...
Zacks
The Zacks Analyst Blog Highlights Biogen, Bristol Myers Squibb, Incyte and Vertex Pharmaceuticals
Biogen, Bristol Myers Squibb, Incyte and Vertex Pharmaceuticals are part of the Zacks top Analyst Blog.
Business Wire
CHMP Adopts Positive Opinion Recommending Approval of Bristol Myers Squibb’s Opdivo® (nivolumab) in Combination with Cisplatin and Gemcitabine for the First-Line Treatment of Adult Patients with Unresectable or Metastatic Urothelial Carcinoma
PRINCETON, N.J., April 26, 2024--CHMP Adopts Positive Opinion Recommending Approval of Bristol Myers Squibb’s Opdivo® (nivolumab) in Combination with Cisplatin and Gemcitabine....